Details

NameSymbolSector
SHUKRA PHARMACEUTICALS LIMITEDSHUKRAPHARPharmaceuticals
Open
34.45
High
34.45
Low
34.45
Close
34.45
Volume
101721
Exchange
bse
Time
03-Oct-2025

Outlook

Score:

1.75

Rating:

RISKY

Candlestick Pattern

CandlepatternofShukraPharmaceuticalsis
Island Reversal
EstimatedStoplossofShukraPharmaceuticalsis
35.86
ShukraPharmaceuticalshasa
Bearishℹ
pattern.
Formationof
Island Reversal
candlepatternindicatesShukraPharmaceuticalshaschancesof
Reversalℹ
todowntrend

Trend

ShukraPharmaceuticalsisin
Uptrendℹ
.
PriceofShukraPharmaceuticalsis
Upℹ
by

26.7

%.
Target
Buy@

20.76

Sell@

35.15

Current@

34.45

Volume

ThetradevolumesofShukraPharmaceuticalshavebecome
Deficientℹ
ThoughthevolumetrendforShukraPharmaceuticalsappears
Bullishℹ
theparticipantsseemtobe
Weak Buyersℹ
ThetradevolumeofShukraPharmaceuticalsis

Down

by

62.88

%

Valuation

ThecurrentmarketpriceofShukraPharmaceuticalsis
Overvaluedℹ

Financials

Balance
Withtotalliablitiesandshareholderequityworth86crandtotalassetsworth86cr,thebalancesheetofShukraPharmaceuticalsis:
Balancedℹ
.
Cashflow
ShukraPharmaceuticalshas
Maintainedℹ
cashflowbecausethereis

Surplus

of

₹ 2cr

.Itis
Downℹ
by

66.67

%.
58.33% i.e. ₹ 7cr earned in operatingℹ
8.33% i.e. ₹ 1cr spent in investingℹ
33.33% i.e. ₹ 4cr spent in financingℹ
0% in otherℹ
ShukraPharmaceuticalshas
Excellentℹ
cashflowbecausethereis

Surplus

of

₹ 6cr

.Itis
Upℹ
by

100

%.
27.78% i.e. ₹ 5cr spent in operatingℹ
5.56% i.e. ₹ 1cr spent in investingℹ
66.67% i.e. ₹ 12cr earned in financingℹ
0% in otherℹ
Income
TheincomeofShukraPharmaceuticalsis

₹ 6cr

and

Profit

is:

₹ 1cr

ShukraPharmaceuticalsProfitisdownby:

80

%andIncomeisDownby:

57.14

%
TheincomeofShukraPharmaceuticalsis

₹ 14cr

and

Profit

is:

₹ 5cr

ShukraPharmaceuticalsProfitisupby:

66.67

%andIncomeisUpby:

27.27

%
TheincomeofShukraPharmaceuticalsis

₹ 11cr

and

Profit

is:

₹ 3cr

ShukraPharmaceuticalsProfitisupby:

300

%andIncomeisUpby:

83.33

%
By using this site you agree to the use of cookies to deliver a better site experience.